Skip to main content
Stock Expert AI
Biotech Brief INTERMEDIATE ✨ AI Enhanced

Lilly's obesity drugs now drive its sales. The stock sits near a high.

4 min read Data as of 5 sources
LLY$1443.50+1.26%Today, Nov 16, 2026: 98/100

AI-generated editorial content. For informational purposes only. Not financial advice.

The Take

  • Eli Lilly and (LLY): Sales engine. Cardiometabolic drugs brought in $19.76B of $24.40B third-quarter revenue, which rose 38.6% from a year earlier.
  • Beat, with a catch. Adjusted EPS of 7.48 topped the estimate of 5.71, but operating margin fell to 35.3%.
  • Next report. Lilly reports again on Feb. 3, 2027, with an EPS estimate of 11.19.
  • 1443.5 USDShare priceAs of
  • 1.26%Day changeAs of
  • 38.6%Revenue vs a year ago
  • 98MoonshotScoreAs of
Eli Lilly booth

Stock Expert AI data cover: figures from Financial Modeling Prep. Photo: Jaireeodell / CC BY-SA 4.0

Weight-loss and diabetes drugs now generate most of Eli Lilly (LLY)'s sales, and revenue rose 38.6% in the third quarter from a year earlier. Revenue was $24.40B in the quarter ended Sept. 30, 2026, above the analyst estimate of $22.58B. The shares traded at 1443.5 USD on the latest quote (Nov. 13, 2026), 1.1% below the 52-week high of 1460 USD.

The idea

The theme is a drugmaker leaning on one drug family. Cardiometabolic drugs treat conditions tied to weight, blood sugar and the heart. When one family becomes the bulk of sales, growth can be fast, but the company's results depend on that one area.

For an investor, the questions are how big that area is, whether profit keeps pace with sales, and what the price already assumes.

The example

In the quarter ended Sept. 30, 2026, Cardiometabolic Health revenue was $19.76B. Oncology was $2.60B, Immunology $1.44B and Neuroscience $444.0M. Cardiometabolic is therefore the large majority of the $24.40B total.

Adjusted earnings per share were 7.48 against an analyst estimate of 5.71, a difference of +$1.77, or 31.0%. Diluted EPS under standard accounting was 7.22, against 6.21 a year earlier. Net income was $6.45B, up 15.6% from a year earlier.

Profit grew more slowly than sales. Operating margin, the share of revenue left after running the business, was 35.3% in the quarter. In the prior quarter ended June 30, 2026, it was 54.2%. The data we have does not say why, and we do not offer a reason.

Cash generation was strong. Free cash flow, the cash left after capital spending, was $8.22B in the quarter. Operating cash flow was $11.40B and capital expenditure was $3.18B.

Sales are also concentrated at home. United States revenue was $15.14B, Europe $4.46B and China $947.0M.

A Zacks report on Nov. 13, 2026 said telehealth company Hims & Hers (HIMS) has partnered with Lilly to offer FDA-approved weight-loss drugs. It is another sign of the category reaching more patients.

Our MoonshotScore for Lilly is 98, with growth the strongest section and valuation the weakest.

Risks

  • Price already high. The trailing price-to-earnings ratio, which compares the share price with profit per share, is 46.73. AbbVie (ABBV) has a P/E of 50.61 and Johnson & Johnson (JNJ) has a P/E of 43.32, while Amgen (AMGN) has 26.79 and AstraZeneca (AZN) has 25.95.
  • Debt. Total debt was $49.50B against cash and short-term investments of $4.88B at Sept. 30, 2026. FMP reports net debt of $44.62B.
  • Margin swing. Operating margin was lower than in the prior quarter. If it stays low, profit may trail sales.

What to watch next

  • Feb. 3, 2027: the next earnings report, 82 days after the Nov. 13, 2026 quote. Analysts estimate EPS of 11.19 and revenue of $24.58B.
  • Operating margin: whether it recovers from 35.3%.
  • Cash returns: buybacks were $377.0M in the third quarter, against $1.60B in the second.
  • Insider activity: the latest filings show 0 open-market purchases and 1 sale in the last 90 days.

Key facts

  • Oct. 29, 2026: Lilly reported adjusted EPS of 7.48 against an estimate of 5.71, and revenue of $24.40B against an estimate of $22.58B.
  • Q3 ended Sept. 30, 2026: net income was $6.45B and operating income was $8.61B.
  • Nov. 13, 2026: the share price was 1443.5 USD, up 1.26% on the latest quote, and 69.7% above the 52-week low of 850.51 USD.
  • Analyst targets: the consensus average target is 1442.44 USD, with a range of 940.00 USD to 1650.00 USD, from 46 ratings with a consensus of Buy.
  • Valuation model: FMP's discounted cash flow model estimates 818.49 USD per share as of Nov. 14, 2026.
MetricQ3 FY2026Q3 FY2025
Revenue$24.40B$17.60B
Operating income$8.61B$8.39B
Net income$6.45B$5.58B
Diluted EPS7.226.21

Frequently asked questions

Q: How much of Eli Lilly's revenue comes from obesity and diabetes drugs?

In the quarter ended Sept. 30, 2026, Cardiometabolic Health revenue was $19.76B out of $24.40B in total revenue, the large majority of sales.

Q: Did Eli Lilly beat estimates in the third quarter?

Yes. Adjusted EPS was 7.48 against an analyst estimate of 5.71, and revenue was $24.40B against an estimate of $22.58B, according to FMP data for the report of Oct. 29, 2026.

Q: When does Eli Lilly report next?

The next earnings date is Feb. 3, 2027. Analysts estimate EPS of 11.19 and revenue of $24.58B for that report.

This is educational content, not investment advice. Past performance does not guarantee future results.

What to watch next

  1. The next earnings report, 82 days after the Nov. 13, 2026 quote. Analysts estimate EPS of 11.19 and revenue of $24.58B.

LLY on Stock Expert AI

MoonshotScore 98/100 Nov 16, 2026

A 0-100 score built from five sections.

  • Quality97
  • Safety93
  • Valuation35
  • Growth100
  • Momentum93
🎯

MoonshotScore AI Ratings

Each stock is scored 0-100 on five pillars: Business Quality, Financial Safety, Valuation, Growth Durability and Momentum. A story quotes the score of the day it was written.

LLY Today, Nov 16, 2026: 98/100

Related Tickers

LLY
biotechnologyearnings

Sources

Related Sectors & Industries

Related 2026 Trends

Next story

Momentum Movers Why did Modine stock rise? A report that Samsung wants to buy it. 4 min readMOD
👁 Editorial Transparency
🧠Content generated by AI editorial engine
👤Stock Expert AI Research is an AI editorial voice of Stock Expert AI
✅Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
🛡Financial Modeling Prep (FMP)
🕑Last updated:

Get the week's earnings in one Thursday email

The S&P 500 companies on that week's earnings calendar, each with its current MoonshotScore, plus the week's Journal research. Free, one email a week, with an unsubscribe link in every issue.

We send one confirmation email first and nothing else until you click its link (it works for 7 days). After that, the Weekly only. Your address is not sold or shared. Newsletter details · Free guide: How to read a MoonshotScore · Privacy Policy


Explore More Market Intelligence

Evidence & Sources

  • Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.
  • MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). Weights are rescaled to 100 when all five pillars have data: 28.3%, 21.7%, 19.6%, 17.4% and 13.0% of the score. It reads no news-sentiment or analyst data, and it is not a probability of future returns.
  • Definitions follow standard investing terminology, with key terms explained inline in plain language where useful.
  • Each price is the last quote we recorded, shown with the trading session it belongs to. Pages are served from a cache, so the copy you are reading can lag that quote. Each quote is a provider snapshot, not an exchange feed.
  • This page is educational and does not constitute investment advice.
  • Numbers come from market data providers (FMP); AI writes the plain-English explanations around them, which should be verified with independent research.